ArticleAdvanced healthcare materials2017
Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
Article in Advanced healthcare materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 82 citations in OpenAlex.
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- Research progress on macrophage regulation of atherosclerosis.Frontiers in cardiovascular medicine · 2026Review
- CD38Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- The Atherosclerotic Plaque Microenvironment as a Therapeutic Target.Current atherosclerosis reports · 2025Review
- Macrophage-based pathogenesis and theranostics of vulnerable plaques.Theranostics · 2025Review
- The Liver X Receptor Promotes Immune Homeostasis via Controlled Activation of the Innate Immune System in the Liver.Biomolecules · 2024Review
- Targeting Macrophage Phenotypes and Metabolism as Novel Therapeutic Approaches in Atherosclerosis and Related Cardiovascular Diseases.Current atherosclerosis reports · 2024Review
- Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.Exploration (Beijing, China) · 2024Review
- Article
- β-carotene accelerates the resolution of atherosclerosis in mice.bioRxiv : the preprint server for biology · 2024Article
- Engineered exosomes as a prospective therapy for diabetic foot ulcers.Burns & trauma · 2024Review
- Biomimetic nanomedicines for precise atherosclerosis theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Advances in drug delivery to atherosclerosis: Investigating the efficiency of different nanomaterials employed for different type of drugs.Materials today. Bio · 2023Review
- The role of efferocytosis-fueled macrophage metabolism in the resolution of inflammation.Immunological reviews · 2023Review
- Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis.Clinical & translational immunology · 2023Article
- Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review.Frontiers in molecular biosciences · 2023Review
- Potential Therapeutic Effect of All-Trans Retinoic Acid on Atherosclerosis.Biomolecules · 2022Review
- Current Development of Nano-Drug Delivery to Target Macrophages.Biomedicines · 2022Review
- Nanotechnology for cardiovascular diseases.Innovation (Cambridge (Mass.)) · 2022Review
- Current advances in the imaging of atherosclerotic vulnerable plaque using nanoparticles.Materials today. Bio · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 4 countries.
Funding
Abstract
The pharmacological manipulation of liver X receptors (LXRs) has been an attractive therapeutic strategy for atherosclerosis treatment as they control reverse cholesterol transport and inflammatory response. This study presents the development and efficacy of nanoparticles (NPs) incorporating the synthetic LXR agonist GW3965 (GW) in targeting atherosclerotic lesions. Collagen IV (Col IV) targeting ligands are employed to functionalize the NPs to improve targeting to the atherosclerotic plaque, and formulation parameters such as the length of the polyethylene glycol (PEG) coating molecules are systematically optimized. In vitro studies indicate that the GW-encapsulated NPs upregulate the LXR target genes and downregulate proinflammatory mediator in macrophages. The Col IV-targeted NPs encapsulating GW (Col IV-GW-NPs) successfully reaches atherosclerotic lesions when administered for 5 weeks to mice with preexisting lesions, substantially reducing macrophage content (≈30%) compared to the PBS group, which is with greater efficacy versus nontargeting NPs encapsulating GW (GW-NPs) (≈18%). In addition, mice administered the Col IV-GW-NPs do not demonstrate increased hepatic lipid biosynthesis or hyperlipidemia during the treatment period, unlike mice injected with the free GW. These findings suggest a new form of LXR-based therapeutics capable of enhanced delivery of the LXR agonist to atherosclerotic lesions without altering hepatic lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.